Skip to main content

Table 1 Patients with concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm reported in the literature

From: Concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm: a case report and literature review

No. (ref.) Age/Sex Preoperative diagnosis Surgery PEN IPMN Postoperative outcome
     Location, size (mm) Pathology1 Location, size (mm), type Pathology2  
1 (3) 51/M PEN DP Tail, 15 Islet cell tumor with nesidioblastosis Tail, ND, ND IPMH (intraductal papillary mucinous hyperplasia) ND
2 (4) 73/M IPMN and PEN DP Tail, 28 Potentially malignant Tail, ND, Branch Benign ND
3 (4) 40/F IPMN and PEN PD Head, 11 Benign Head, ND, Branch Benign ND
4 (4) 61/F IPMN DP Tail, 12 Benign Tail, ND, Mixed Borderline ND
5 (4) 55/F PEN PD Head, 30 Malignant (duodenal wall invasion, peripancreatic lymph nodes metastases) Head, ND, Mixed Benign ND
6 (4) 68/F IPMN and PEN DP Body, 18 Benign Body, ND, Mixed Benign ND
7 (4) 62/M IPMN PD Head, 20 Potentially malignant Head, ND, Mixed Malignant noninvasive ND
8 (5) 65/F IPMN TP Body, 2 Benign Head, Body, 40, Mixed Malignant invasive Disease-free, 10 months
9 (5) 66/M IPMN TP Tail, 5 Benign Entire, 150, Mixed Malignant invasive Alive, 70 months
10 (5) 58/M IPMN DP Tail, 8 Benign Tail, 18, Branch Borderline Alive, 5 months
11 (6) 72/F ND PD Head, 25 PDNC (resional lymph nodes metastases) Head, ND, ND Borderline malignant potential Died, 10 months
12 (7) 75/M IPMN PD Head, 35 WDNC (peripancreatic lymph nodes metastases) Head, 35, Mixed Moderately to poorly differentiated adenocarcinoma Died, 6 months
13 (8) 54/F ND PD Head, ND ND Head, 25, Branch Benign ND
14 (9) 59/F IPMN and PEN observation Body, 7.8 Benign Body, Tail, 10 the largest, Branch ND Alive, 12 months
15 (9) 55/F IPMN and PEN enucleation Head, 20 Low malignant potential Head, 5,6,7, Branch ND ND
16 (10) 67/M IPMN TP Head, 8 WDNT Diffuse, 20, Main Low grade dysplasia ND
17 (10) 72/F IPMN and PEN DP Tail, 16 WDNC (peripancreatic lymph nodes metastases) Body, 9, Branch Low grade dysplasia ND
18 (10) 72/F IPMN DP Body, 9 WDNT Body, 15, Branch Low grade dysplasia ND
19 (10) 76/F IPMN TP Head, 11 WDNT Head, 27, Branch Well differentiated adenocarcinoma ND
20 74/M IPMN PD Head, 3 WDNT/NET G1 Head, 10, Mixed Low grade dysplasia Alive, 12 months
  1. 1. Pathology of PEN is described according to WHO 2000 criteria, as this was used in all prior studies. As for the present case, the pathology of the PEN is described according to both WHO 2000 and 2010 criteria.
  2. 2. The pathology of IPMN is described according to criteria in prior studies [15]. As for the present case, the pathology of IPMN is described according to WHO 2010 criteria [16].
  3. Branch, branch type IPMN; DP, distal pancreatectomy; G1, Neuroendocrine tumor G1; IPMN, intraductal papillary mucinous neoplasm; Main, main duct type IPMN; Mixed, mixed type IPMN; ND, not described; PD, pancreatoduodenectomy; PDNC, poorly differentiated neuroendocrine carcinoma; PEN, pancreatic endocrine neoplasm; TP, total pancreatectomy; WDNC, well differentiated neuroendocrine carcinoma; WDNT, well-differentiated neuroendocrine tumor.